DCPrime completes DCP-001 Phase I/IIa study in patients with acute myeloid leukemia

May 28 2013

Cancer vaccine company DCPrime today announced the successful completion of its Phase I/IIa study in acute myeloid leukemia (AML). The study establishes the safety and feasibility of vaccination with DCPrime's lead product DCP-001, and shows clear evidence of a positive, vaccination induced immune response. Remarkably, several patients showed prolonged survival compared to historic expectations.

“We are very pleased with the encouraging results from this study”

"Given the stage of disease of these patients, the results of our study are compelling, and provide us with a solid basis to advance our lead product DCP-001 to a multicenter Phase II study in a larger patient population and continue the development of this promising treatment for AML," said Marcel Zwaal, CEO.

"We are very pleased with the encouraging results from this study," said Prof. Dr. Arjan van de Loosdrecht, principal investigator and professor of hematology at VUmc. "Dendritic cell vaccines such as DCP-001 may offer AML patients a real and much needed therapeutic alternative in the near future. We look forward to working with the Company to further develop DCP-001 in a multicenter randomized Phase II trial."